APO Research
Talk to an analyst

APO RESEARCH · REPORT

Microbiome Drugs

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

Selected research

Market Outlook & Growth Opportunities

Global Microbiome Drugs Market Outlook and Growth Opportunities 2026

30 December 2025208 pages

Choose your research edition.

Industry ResearchMicrobiome Drugs Industry Research Report 2026127 pages · $2,950 USDIndustry Growth & TrendsGlobal Microbiome Drugs Industry Growth and Trends Forecast to 2032110 pages · $3,450 USDMarket StructureGlobal Microbiome Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Microbiome Drugs Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal Microbiome Drugs Market Analysis and Forecast 2026-2032206 pages · $4,950 USD

Market perspective

Microbiome Drug is a kind of medicine made with microorganisms. According to the source, it is divided into three categories: drugs derived from whole or part of microorganisms, drugs derived from microbial primary metabolites, and drugs derived from microbial secondary metabolites.

North America and Europe hold most of market share of microbiome drugs, and North America occupies a share over 77%, on the other hand, Europe takes a share of over 22% in total. Global core microbiome drugs manufacturers include Seres Therapeutics, Assembly Biosciences, Synthetic Biologics etc.

This report provides an overview of the global Microbiome Drugs market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

Read the full market overview

The study covers key producers of Microbiome Drugs and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Microbiome Drugs revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Microbiome Drugs market.

Microbiome Drugs Segment by Company

Seres Therapeutics

Assembly Biosciences

Synthetic Biologics

Interxon

PureTech

Synlogic

Enterome BioScience

4D Pharma

Second Genome

AOBiome

Rebiotix

Metabiomics

Ritter Pharmaceuticals

Symberix

OpenBiome

Azitra

Osel

Microbiome Drugs Segment by Type

Oral Dosage Form

Enteric Capsules

Microbiome Drugs Segment by Symptom

Gastrointestinal Disorders

Autoimmune Disorders

Diabetes

Cancer

Others

Microbiome Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Microbiome Drugs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Microbiome Drugs key companies, revenue, market share, and recent developments.

3. To split the Microbiome Drugs breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Microbiome Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Microbiome Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze Microbiome Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Microbiome Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Microbiome Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Microbiome Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Microbiome Drugs industry.

Chapter 3: Detailed analysis of Microbiome Drugs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Microbiome Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Microbiome Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Microbiome Drugs Industry Trends Table 2. Microbiome Drugs Industry Drivers Table 3. Microbiome Drugs Industry Opportunities and Challenges Table 4. Microbiome Drugs Industry Restraints Table 5. Global Microbiome Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Microbiome Drugs Revenue Share by Company (2021-2026) Table 7. Global Microbiome Drugs Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Microbiome Drugs Key Company Manufacturing Base & Headquarters Table 9. Global Microbiome Drugs Company, Product Type & Application Table 10. Global Microbiome Drugs Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Microbiome Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Oral Dosage Form Table 15. Significant Companies of Enteric Capsules Table 16. Global Microbiome Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Microbiome Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Microbiome Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Microbiome Drugs Sales Value Share by Type (2021-2026) Table 20. Global Microbiome Drugs Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Gastrointestinal Disorders Table 22. Significant Companies of Autoimmune Disorders Table 23. Significant Companies of Diabetes Table 24. Significant Companies of Cancer Table 25. Significant Companies of Others Table 26. Global Microbiome Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Microbiome Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Microbiome Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Microbiome Drugs Sales Value Share by Application (2021-2026) Table 30. Global Microbiome Drugs Sales Value Share by Application (2027-2032) Table 31. Global Microbiome Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Microbiome Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Microbiome Drugs Sales Value Share by Region (2021-2026) Table 34. Global Microbiome Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Microbiome Drugs Sales Value Share by Region (2027-2032) Table 36. Global Microbiome Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Microbiome Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Microbiome Drugs Sales Value Market Share by Country (2021-2026) Table 39. Global Microbiome Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Microbiome Drugs Sales Value Market Share by Country (2027-2032) Table 41. Seres Therapeutics Company Information Table 42. Seres Therapeutics Business Overview Table 43. Seres Therapeutics Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Seres Therapeutics Microbiome Drugs Product Portfolio Table 45. Seres Therapeutics Recent Development Table 46. Assembly Biosciences Company Information Table 47. Assembly Biosciences Business Overview Table 48. Assembly Biosciences Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. Assembly Biosciences Microbiome Drugs Product Portfolio Table 50. Assembly Biosciences Recent Development Table 51. Synthetic Biologics Company Information Table 52. Synthetic Biologics Business Overview Table 53. Synthetic Biologics Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Synthetic Biologics Microbiome Drugs Product Portfolio Table 55. Synthetic Biologics Recent Development Table 56. Interxon Company Information Table 57. Interxon Business Overview Table 58. Interxon Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Interxon Microbiome Drugs Product Portfolio Table 60. Interxon Recent Development Table 61. PureTech Company Information Table 62. PureTech Business Overview Table 63. PureTech Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. PureTech Microbiome Drugs Product Portfolio Table 65. PureTech Recent Development Table 66. Synlogic Company Information Table 67. Synlogic Business Overview Table 68. Synlogic Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Synlogic Microbiome Drugs Product Portfolio Table 70. Synlogic Recent Development Table 71. Enterome BioScience Company Information Table 72. Enterome BioScience Business Overview Table 73. Enterome BioScience Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Enterome BioScience Microbiome Drugs Product Portfolio Table 75. Enterome BioScience Recent Development Table 76. 4D Pharma Company Information Table 77. 4D Pharma Business Overview Table 78. 4D Pharma Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. 4D Pharma Microbiome Drugs Product Portfolio Table 80. 4D Pharma Recent Development Table 81. Second Genome Company Information Table 82. Second Genome Business Overview Table 83. Second Genome Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Second Genome Microbiome Drugs Product Portfolio Table 85. Second Genome Recent Development Table 86. AOBiome Company Information Table 87. AOBiome Business Overview Table 88. AOBiome Microbiome Drugs Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. AOBiome Microbiome Drugs Product Portfolio Table 90. AOBiome Recent Development Table 91. Rebiotix Company Information Table 92. Rebiotix Business Overview Table 93. Rebiotix Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 94. Rebiotix Microbiome Drugs Product Portfolio Table 95. Rebiotix Recent Development Table 96. Metabiomics Company Information Table 97. Metabiomics Business Overview Table 98. Metabiomics Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 99. Metabiomics Microbiome Drugs Product Portfolio Table 100. Metabiomics Recent Development Table 101. Ritter Pharmaceuticals Company Information Table 102. Ritter Pharmaceuticals Business Overview Table 103. Ritter Pharmaceuticals Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 104. Ritter Pharmaceuticals Microbiome Drugs Product Portfolio Table 105. Ritter Pharmaceuticals Recent Development Table 106. Symberix Company Information Table 107. Symberix Business Overview Table 108. Symberix Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 109. Symberix Microbiome Drugs Product Portfolio Table 110. Symberix Recent Development Table 111. OpenBiome Company Information Table 112. OpenBiome Business Overview Table 113. OpenBiome Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 114. OpenBiome Microbiome Drugs Product Portfolio Table 115. OpenBiome Recent Development Table 116. Azitra Company Information Table 117. Azitra Business Overview Table 118. Azitra Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 119. Azitra Microbiome Drugs Product Portfolio Table 120. Azitra Recent Development Table 121. Osel Company Information Table 122. Osel Business Overview Table 123. Osel Microbiome Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 124. Osel Microbiome Drugs Product Portfolio Table 125. Osel Recent Development Table 126. Research Programs/Design for This Report Table 127. Authors List of This Report Table 128. Secondary Sources Table 129. Primary Sources List of Figures Figure 1. Microbiome Drugs Product Image Figure 2. Global Microbiome Drugs Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Microbiome Drugs Market Size (2021-2032) & (US$ Million) Figure 4. Global Microbiome Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Oral Dosage Form Image Figure 8. Enteric Capsules Image Figure 9. Global Microbiome Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Microbiome Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Microbiome Drugs Sales Value Share by Type (2021-2032) Figure 12. Gastrointestinal Disorders Image Figure 13. Autoimmune Disorders Image Figure 14. Diabetes Image Figure 15. Cancer Image Figure 16. Others Image Figure 17. Global Microbiome Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Microbiome Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Microbiome Drugs Sales Value Share by Application (2021-2032) Figure 20. Global Microbiome Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Microbiome Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Microbiome Drugs Sales Value (2021-2032) & (US$ Million) Figure 23. North America Microbiome Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Microbiome Drugs Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Microbiome Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Microbiome Drugs Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Microbiome Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Microbiome Drugs Sales Value (2021-2032) & (US$ Million) Figure 29. South America Microbiome Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Microbiome Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Microbiome Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Microbiome Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Microbiome Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Microbiome Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Oral Dosage Form
  • Enteric Capsules
Applications
  • Gastrointestinal Disorders
  • Autoimmune Disorders
  • Diabetes
  • Cancer
  • Others
Companies covered
  • Seres Therapeutics
  • Assembly Biosciences
  • Synthetic Biologics
  • Interxon
  • PureTech
  • Synlogic
  • Enterome BioScience
  • 4D Pharma
  • Second Genome
  • AOBiome
  • Rebiotix
  • Metabiomics
  • Ritter Pharmaceuticals
  • Symberix
  • OpenBiome
  • Azitra
  • Osel

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Microbiome Drugs Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Microbiome Drugs Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Microbiome Drugs Market Dynamics
  1. 2.1 Microbiome Drugs Industry Trends
  2. 2.2 Microbiome Drugs Industry Drivers
  3. 2.3 Microbiome Drugs Industry Opportunities and Challenges
  4. 2.4 Microbiome Drugs Industry Restraints
3 Microbiome Drugs Market by Company
  1. 3.1 Global Microbiome Drugs Company Revenue Ranking in 2025
  2. 3.2 Global Microbiome Drugs Revenue by Company (2021-2026)
  3. 3.3 Global Microbiome Drugs Company Ranking (2024-2026)
  4. 3.4 Global Microbiome Drugs Company Manufacturing Base and Headquarters
  5. 3.5 Global Microbiome Drugs Company Product Type and Application
  6. 3.6 Global Microbiome Drugs Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Microbiome Drugs Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Microbiome Drugs Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Microbiome Drugs Market by Type
  1. 4.1 Microbiome Drugs Type Introduction
  2. 4.1.1 Oral Dosage Form
  3. 4.1.2 Enteric Capsules
  4. 4.2 Global Microbiome Drugs Sales Value by Type
  5. 4.2.1 Global Microbiome Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Microbiome Drugs Sales Value by Type (2021-2032)
  7. 4.2.3 Global Microbiome Drugs Sales Value Share by Type (2021-2032)
5 Microbiome Drugs Market by Application
  1. 5.1 Microbiome Drugs Application Introduction
  2. 5.1.1 Gastrointestinal Disorders
  3. 5.1.2 Autoimmune Disorders
  4. 5.1.3 Diabetes
  5. 5.1.4 Cancer
  6. 5.1.5 Others
  7. 5.2 Global Microbiome Drugs Sales Value by Application
  8. 5.2.1 Global Microbiome Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  9. 5.2.2 Global Microbiome Drugs Sales Value by Application (2021-2032)
  10. 5.2.3 Global Microbiome Drugs Sales Value Share by Application (2021-2032)
6 Microbiome Drugs Regional Value Analysis
  1. 6.1 Global Microbiome Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Microbiome Drugs Sales Value by Region (2021-2032)
  3. 6.2.1 Global Microbiome Drugs Sales Value by Region: 2021-2026
  4. 6.2.2 Global Microbiome Drugs Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Microbiome Drugs Sales Value (2021-2032)
  7. 6.3.2 North America Microbiome Drugs Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Microbiome Drugs Sales Value (2021-2032)
  10. 6.4.2 Europe Microbiome Drugs Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Microbiome Drugs Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Microbiome Drugs Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Microbiome Drugs Sales Value (2021-2032)
  16. 6.6.2 South America Microbiome Drugs Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Microbiome Drugs Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Microbiome Drugs Sales Value Share by Country, 2025 VS 2032
7 Microbiome Drugs Country-level Value Analysis
  1. 7.1 Global Microbiome Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Microbiome Drugs Sales Value by Country (2021-2032)
  3. 7.2.1 Global Microbiome Drugs Sales Value by Country (2021-2026)
  4. 7.2.2 Global Microbiome Drugs Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Microbiome Drugs Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Microbiome Drugs Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Microbiome Drugs Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Microbiome Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Microbiome Drugs Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Microbiome Drugs Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Microbiome Drugs Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Microbiome Drugs Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Microbiome Drugs Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Microbiome Drugs Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Microbiome Drugs Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Microbiome Drugs Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Microbiome Drugs Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Microbiome Drugs Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Microbiome Drugs Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Microbiome Drugs Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Microbiome Drugs Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Microbiome Drugs Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Microbiome Drugs Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Microbiome Drugs Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Microbiome Drugs Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Microbiome Drugs Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Microbiome Drugs Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Microbiome Drugs Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Microbiome Drugs Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Microbiome Drugs Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Microbiome Drugs Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Microbiome Drugs Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Microbiome Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Microbiome Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Seres Therapeutics
  2. 8.1.1 Seres Therapeutics Company Information
  3. 8.1.2 Seres Therapeutics Business Overview
  4. 8.1.3 Seres Therapeutics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Seres Therapeutics Microbiome Drugs Product Portfolio
  6. 8.1.5 Seres Therapeutics Recent Developments
  7. 8.2 Assembly Biosciences
  8. 8.2.1 Assembly Biosciences Company Information
  9. 8.2.2 Assembly Biosciences Business Overview
  10. 8.2.3 Assembly Biosciences Microbiome Drugs Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Assembly Biosciences Microbiome Drugs Product Portfolio
  12. 8.2.5 Assembly Biosciences Recent Developments
  13. 8.3 Synthetic Biologics
  14. 8.3.1 Synthetic Biologics Company Information
  15. 8.3.2 Synthetic Biologics Business Overview
  16. 8.3.3 Synthetic Biologics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Synthetic Biologics Microbiome Drugs Product Portfolio
  18. 8.3.5 Synthetic Biologics Recent Developments
  19. 8.4 Interxon
  20. 8.4.1 Interxon Company Information
  21. 8.4.2 Interxon Business Overview
  22. 8.4.3 Interxon Microbiome Drugs Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Interxon Microbiome Drugs Product Portfolio
  24. 8.4.5 Interxon Recent Developments
  25. 8.5 PureTech
  26. 8.5.1 PureTech Company Information
  27. 8.5.2 PureTech Business Overview
  28. 8.5.3 PureTech Microbiome Drugs Revenue and Gross Margin (2021-2026)
  29. 8.5.4 PureTech Microbiome Drugs Product Portfolio
  30. 8.5.5 PureTech Recent Developments
  31. 8.6 Synlogic
  32. 8.6.1 Synlogic Company Information
  33. 8.6.2 Synlogic Business Overview
  34. 8.6.3 Synlogic Microbiome Drugs Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Synlogic Microbiome Drugs Product Portfolio
  36. 8.6.5 Synlogic Recent Developments
  37. 8.7 Enterome BioScience
  38. 8.7.1 Enterome BioScience Company Information
  39. 8.7.2 Enterome BioScience Business Overview
  40. 8.7.3 Enterome BioScience Microbiome Drugs Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Enterome BioScience Microbiome Drugs Product Portfolio
  42. 8.7.5 Enterome BioScience Recent Developments
  43. 8.8 4D Pharma
  44. 8.8.1 4D Pharma Company Information
  45. 8.8.2 4D Pharma Business Overview
  46. 8.8.3 4D Pharma Microbiome Drugs Revenue and Gross Margin (2021-2026)
  47. 8.8.4 4D Pharma Microbiome Drugs Product Portfolio
  48. 8.8.5 4D Pharma Recent Developments
  49. 8.9 Second Genome
  50. 8.9.1 Second Genome Company Information
  51. 8.9.2 Second Genome Business Overview
  52. 8.9.3 Second Genome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Second Genome Microbiome Drugs Product Portfolio
  54. 8.9.5 Second Genome Recent Developments
  55. 8.10 AOBiome
  56. 8.10.1 AOBiome Company Information
  57. 8.10.2 AOBiome Business Overview
  58. 8.10.3 AOBiome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  59. 8.10.4 AOBiome Microbiome Drugs Product Portfolio
  60. 8.10.5 AOBiome Recent Developments
  61. 8.11 Rebiotix
  62. 8.11.1 Rebiotix Company Information
  63. 8.11.2 Rebiotix Business Overview
  64. 8.11.3 Rebiotix Microbiome Drugs Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Rebiotix Microbiome Drugs Product Portfolio
  66. 8.11.5 Rebiotix Recent Developments
  67. 8.12 Metabiomics
  68. 8.12.1 Metabiomics Company Information
  69. 8.12.2 Metabiomics Business Overview
  70. 8.12.3 Metabiomics Microbiome Drugs Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Metabiomics Microbiome Drugs Product Portfolio
  72. 8.12.5 Metabiomics Recent Developments
  73. 8.13 Ritter Pharmaceuticals
  74. 8.13.1 Ritter Pharmaceuticals Company Information
  75. 8.13.2 Ritter Pharmaceuticals Business Overview
  76. 8.13.3 Ritter Pharmaceuticals Microbiome Drugs Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Ritter Pharmaceuticals Microbiome Drugs Product Portfolio
  78. 8.13.5 Ritter Pharmaceuticals Recent Developments
  79. 8.14 Symberix
  80. 8.14.1 Symberix Company Information
  81. 8.14.2 Symberix Business Overview
  82. 8.14.3 Symberix Microbiome Drugs Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Symberix Microbiome Drugs Product Portfolio
  84. 8.14.5 Symberix Recent Developments
  85. 8.15 OpenBiome
  86. 8.15.1 OpenBiome Company Information
  87. 8.15.2 OpenBiome Business Overview
  88. 8.15.3 OpenBiome Microbiome Drugs Revenue and Gross Margin (2021-2026)
  89. 8.15.4 OpenBiome Microbiome Drugs Product Portfolio
  90. 8.15.5 OpenBiome Recent Developments
  91. 8.16 Azitra
  92. 8.16.1 Azitra Company Information
  93. 8.16.2 Azitra Business Overview
  94. 8.16.3 Azitra Microbiome Drugs Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Azitra Microbiome Drugs Product Portfolio
  96. 8.16.5 Azitra Recent Developments
  97. 8.17 Osel
  98. 8.17.1 Osel Company Information
  99. 8.17.2 Osel Business Overview
  100. 8.17.3 Osel Microbiome Drugs Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Osel Microbiome Drugs Product Portfolio
  102. 8.17.5 Osel Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst